# Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

> **NCT00171340** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1065 (actual)

## Conditions studied

- Bone Loss
- Breast Cancer

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT00171340
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 1065 (ACTUAL)
- **Last updated:** 2012-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171340, "Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00171340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*